Ficlatuzumab is a humanized monoclonal antibody designed to target hepatocyte growth factor (HGF), also known as scatter factor (SF). Its primary application lies in oncology, particularly in the inhibition of tumor growth and metastasis. By neutralizing HGF, ficlatuzumab blocks the activation of the c-Met receptor, a key signaling pathway involved in cell proliferation, survival, migration, and angiogenesis—processes often hijacked by cancer cells. This antibody has been investigated in clinical trials for various solid tumors, including non-small cell lung cancer (NSCLC), where dysregulation of the HGF/c-Met pathway is associated with poor prognosis and resistance to therapy. Ficlatuzumab is studied both as a monotherapy and in combination with other agents, such as EGFR inhibitors, to overcome resistance and enhance treatment efficacy. Its use aims to suppress tumor progression and improve patient outcomes in cancers dependent on HGF/c-Met signaling.